Fol. Biol. 2003, 49, 203-206
https://doi.org/10.14712/fb2003049050203
Immunotherapy of HPV 16-Associated Tumours with Tumour Cell Line/Dendritic Cell Line (TC-1/DC2.4) Hybrid Vaccines
Individual author index pages
Other articles of these authors
-
Serum Levels of Matrix Metalloproteinases 2 and 9 in Patients with Acute Myocardial Infarction
Jana Šímová, J. Škvor, D. Slovák, I. Mazura, J. Zvárová
2013, Vol. 59, Issue 5, pp. 181-187 -
Serum Levels of Matrix Metalloproteinases 2 and 9 and TGFBR2 Gene Screening in Patients with Ascending Aortic Dilatation
Jana Šímová, J. Škvor, J. Reissigová, J. Dudra, J. Lindner, P. Čapek, J. Zvárová
2013, Vol. 59, Issue 4, pp. 154-161 -
Genetically Modified Vaccines Augment the Efficacy of Cancer Surgery and Chemotherapy
J. Bubeník
2009, Vol. 55, Issue 6, pp. 199-200 -
Immunotherapeutic Efficacy of Vaccines Generated by Fusion of Dendritic Cells and HPV16-Associated Tumour Cells
Jana Šímová, J. Bubeník, J. Bieblová, M. Indrová, T. Jandlová
2005, Vol. 51, Issue 1, pp. 19-24 -
Immunogenicity of Dendritic Cell-Based HPV16 E6/E7 Peptide Vaccines: CTL Activation and Protective Effects
Marie Indrová, M. Reiniš, J. Bubeník, T. Jandlová, J. Bieblová, V. Vonka, J. Velek
2004, Vol. 50, Issue 6, pp. 184-193 -
The Role of NK1.1+ Cells in the Protection against MHC Class I+ HPV16-Associated Tumours
Jana Šímová, J. Bubeník, J. Bieblová, T. Jandlová
2004, Vol. 50, Issue 6, pp. 200-202 -
Adjuvant Cytokine Treatment of Minimal Residual Disease after Surgical Therapy in Mice Carrying HPV16-Associated Tumours: Cytolytic Activity of Spleen Cells from Tumour Regressors
Marie Indrová, R. Mikyšková, T. Jandlová, V. Vonka, J. Bubeník, J. Bieblová
2003, Vol. 49, Issue 6, pp. 217-222 -
MHC Class I+ and Class I- HPV16-Associated Tumours Expressing the E7 Oncoprotein Do Not Cross-react in Immunization/Challenge Experiments
Jana Šímová, R. Mikyšková, V. Vonka, J. Bieblová, J. Bubeník, T. Jandlová
2003, Vol. 49, Issue 6, pp. 230-234
